The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Gilead tested lenacapavir—which was approved by the FDA in 2022 as a treatment for patients with drug-resistant HIV—in two clinical trials against its daily prophylactic pills.

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.